India has proposed zero tariffs on steel, auto components and pharmaceuticals on a reciprocal basis up to a certain quantity of imports in its trade negotiations with the US, people familiar with the matter said.
Beyond this threshold, imported industrial goods would attract the regular level of duties, the people said, asking not to be identified as the discussions are private. The offer was made by Indian trade officials visiting Washington late last month to expedite negotiations on a bilateral trade deal expected by fall this year, the people said.
The two nations are prioritizing certain sectors to strike an early trade deal before the end of the 90-day pause on US President Donald Trump’s tit-for-tat tariffs, the people said.
Amid a contraction in the US economy, Trump suggested Sunday that some trade deals could be sealed as soon as this week, offering the prospect of relief for trading partners seeking to avoid higher US import duties. Asian economies, including South Korea, Japan and India are among the nations leading the race for reaching interim deals with his administration.
An email to India’s Ministry of Commerce and Industry was not immediately answered.
Washington has also asked India to resolve its concerns around Quality Control Orders, which it considers a non-tariff trade barrier for its exports, the people said. The mandatory quality standards, which lay down benchmarks that both local and foreign manufacturers must meet before selling their goods in India, have been criticized for being non-transparent and unfair.
India is willing to reconsider its existing QCOs in sectors such as medical devices and chemicals, and has offered to sign a mutual recognition agreement with the US under which both nations will accept each other’s regulatory standards and practices.
It’s unclear if these proposals will form part of the final deal.
From just 14 QCOs before 2014, the number has gone up to more than 140 since 2017, a report showed.
Beyond this threshold, imported industrial goods would attract the regular level of duties, the people said, asking not to be identified as the discussions are private. The offer was made by Indian trade officials visiting Washington late last month to expedite negotiations on a bilateral trade deal expected by fall this year, the people said.
The two nations are prioritizing certain sectors to strike an early trade deal before the end of the 90-day pause on US President Donald Trump’s tit-for-tat tariffs, the people said.
Amid a contraction in the US economy, Trump suggested Sunday that some trade deals could be sealed as soon as this week, offering the prospect of relief for trading partners seeking to avoid higher US import duties. Asian economies, including South Korea, Japan and India are among the nations leading the race for reaching interim deals with his administration.
An email to India’s Ministry of Commerce and Industry was not immediately answered.
Washington has also asked India to resolve its concerns around Quality Control Orders, which it considers a non-tariff trade barrier for its exports, the people said. The mandatory quality standards, which lay down benchmarks that both local and foreign manufacturers must meet before selling their goods in India, have been criticized for being non-transparent and unfair.
India is willing to reconsider its existing QCOs in sectors such as medical devices and chemicals, and has offered to sign a mutual recognition agreement with the US under which both nations will accept each other’s regulatory standards and practices.
It’s unclear if these proposals will form part of the final deal.
From just 14 QCOs before 2014, the number has gone up to more than 140 since 2017, a report showed.
You may also like
Zhao Xintong beats Mark Williams to win historic World Snooker Championship title
IIT-Kharagpur relaxes rules after suicides
In a boost to Civil Defence amid tensions with Pakistan, MHA to organise rehearsal across 244 categorised districts on May 7
Brits risk hefty fines when driving abroad for making these common mistakes
Tennis star in 'unbearable pain' and relying on tablets releases emotional statement
